1331 related articles for article (PubMed ID: 17056312)
1. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
3. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
5. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Dörler J; Edlinger M; Alber HF; Altenberger J; Benzer W; Grimm G; Huber K; Pachinger O; Schuchlenz H; Siostrzonek P; Zenker G; Weidinger F;
Eur Heart J; 2011 Dec; 32(23):2954-61. PubMed ID: 21920970
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
[TBL] [Abstract][Full Text] [Related]
8. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
9. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).
Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL;
Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147
[TBL] [Abstract][Full Text] [Related]
10. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT;
Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857
[TBL] [Abstract][Full Text] [Related]
11. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
12. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
13. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
[TBL] [Abstract][Full Text] [Related]
14. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
15. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
17. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
Montalescot G; Van de Werf F; Gulba DC; Avezum A; Brieger D; Kennelly BM; Mazurek T; Spencer F; White K; Gore JM;
Catheter Cardiovasc Interv; 2003 Nov; 60(3):360-7. PubMed ID: 14571488
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System.
Srinivas VS; Skeif B; Negassa A; Bang JY; Shaqra H; Monrad ES
Am J Cardiol; 2007 Feb; 99(4):482-5. PubMed ID: 17293189
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
[TBL] [Abstract][Full Text] [Related]
20. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
